COVID-19 Infection After Different Combinations of Vaccines in Patients with Solid Tumors
Oktay Unsal1, Ozan Yazici1, Nuriye Ozdemir1, Gozde Savas1, Ahmet Ozet11Department of Medical Oncology, Gazi University Faculty of Medicine Ankara, Türkiye
Objectives: This study aimed to evaluate the cancer patients with COVID-19 infection after receiving different combinations of the COVID-19 vaccines for effective vaccination strategies. Methods: Eighty nine point thirty three percent (89.33%) of 3832 with solid malignancy were received at least 2 doses of COVID-19 vaccine. A total of 167 cancer patients with COVID-19 infection at least 28 days after the last dose of COVID-19 vaccine were included in the study. Results: Forty one point nine percent (41.9%) of the study population were received two doses of CoronaVac vaccine, 21.5% of the them; two doses of CoronaVac vaccine and one dose of BNT162b2 vaccine, 18.6% of them; two doses of BNT162b2 vaccine and 18% of them; three doses of CoronaVac vaccine. The median day from the last dose of vaccination to infection was significantly longer in patients with receiving cytotoxic chemotherapy than others (p=0.02). The requirement of oxygen support was high numerically in patients received the last of cytotoxic chemotherapy in 1-14 days prior to COVID-19 infection (23%). Conclusion: This study outlined the similar efficacy of the different combinations of COVID-19 vaccine by evaluating the clinical parameters in patients with solid malignancy. Keywords: BNT162b2 vaccine, COVID-19 infection, CoronaVac vaccine
Cite This Article
Unsal O, Yazici O, Ozdemir N, Savas G, Ozet A. COVID-19 Infection After Different Combinations of Vaccines in Patients with Solid Tumors. EJMI. 2023; 7(4): 419-425
Corresponding Author: Oktay Unsal